<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the <em>KDR</em> Gene Polymorphism</p>

Abstract

The clinical outcomes of treatment with apatinib mesylate for advanced non-squamous NSCLC in patients who progressed after standard therapy may be influenced by the <i>KDR</i> 4397T>C polymorphism through mediation of the mRNA expression of <i>KDR</i>.